Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

被引：0

作者：

Manfredi, G. F. ^{[1
,2
]}

Fulgenzi, C. A. M. ^{[2
]}

D'Alessio, A. ^{[2
,3
]}

Celsa, C. ^{[2
,4
,5
]}

Stefanini, B. ^{[2
,6
]}

Cheon, J. ^{[7
]}

Ang, C. ^{[8
]}

Marron, T. U. ^{[8
]}

Saeed, A. ^{[9
]}

Wietharn, B. ^{[9
]}

Pressiani, T. ^{[10
]}

Pinter, M. ^{[11
]}

Scheiner, B. ^{[11
]}

Huang, Yi-Hsiang ^{[12
,13
]}

Phen, S. ^{[14
]}

Naqash, A. Rafeh ^{[15
]}

Piscaglia, F. ^{[6
]}

Lin, R. Po-Ting ^{[16
,17
]}

Lin, C. -yen ^{[16
,17
]}

Dalbeni, A. ^{[18
,19
]}

Vivaldi, C. ^{[20
,21
]}

Masi, G. ^{[20
,21
]}

Thimme, R. ^{[22
]}

Vogel, A. ^{[23
,24
,25
]}

Schonlein, M. ^{[26
]}

von Felden, J. ^{[27
]}

Schulze, K. ^{[27
]}

Wege, H. ^{[27
]}

Galle, P. R. ^{[28
]}

Kudo, M. ^{[29
]}

Rimassa, L. ^{[10
,30
]}

Singal, A. ^{[14
]}

Sharma, R. ^{[2
]}

Cortellini, A. ^{[1
,31
]}

Chon, H. Jae ^{[7
]}

Burlone, M. ^{[32
]}

Pirisi, M. ^{[1
,32
]}

Pinato, D. J. ^{[2
,3
]}

机构：

[1] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London, England

[3] Univ Piemonte Orientale, Div Oncol, Dept Translat Med, Novara, Italy

[4] Univ Palermo, Sect Gastroenterol & Hepatol, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy

[5] Univ Palermo, Dept Surg Oncol & Oral Sci Di Chir On S, Palermo, Italy

[6] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[7] CHA Univ, Dept Internal Med, CHA Bundang Med Ctr, Med Oncol, Seongnam, South Korea

[8] Tisch Canc Inst, Mt Sinai Hosp, Div Hematol Oncol, Dept Med, New York, NY USA

[9] Kansas Univ, Div Med Oncol, Dept Med, Canc Ctr, Kansas City, KS USA

[10] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Via A Manzoni 56, I-20089 Rozzano, Milan, Italy

[11] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria

[12] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan

[13] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Sch Med, Taipei, Taiwan

[14] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[15] Univ Oklahoma, Med Oncol, Stephenson Canc Ctr, TSET Phase 1 Program, Oklahoma City, OK USA

[16] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Linkou Med Ctr, Taoyuan, Taiwan

[17] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[18] Univ Verona, Dept Med, Gen Med C Unit, Verona, Italy

[19] Univ Verona, Liver Unit, Verona, Italy

[20] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[21] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[22] Univ Freiburg, Freiburg Univ Med Ctr, Dept Med Gastroenterol Hepatol Endocrinol & Infec, Fac Med, Freiburg, Germany

[23] UHN, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada

[24] Princess Margaret Canc Ctr, Toronto, ON, Canada

[25] Hannover Med Sch, Hannover, Germany

[26] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany

[27] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany

[28] Univ Med Ctr Mainz, Dept Internal Med 1, Mainz, Germany

[29] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[30] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy

[31] Fdn Policlin Univ Campus Biomed, Med Oncol, Rome, Italy

[32] AOU Maggiore Carita, Div Internal Med, Novara, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

10.1016/j.dld.2024.01.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OC-11

引用

页码：S8 / S9

页数：2

共 50 条

[21] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
Hwang, Sang Youn
Woo, Hyun Young
Heo, Jeong
Kim, Hyung Jun
Park, Young Joo
Yi, Ki Youn
Lee, Yu Rim
Park, Soo Young
Chung, Woo Jin
Jang, Byoung Kuk
Tak, Won Young
CANCERS, 2024, 16 (04)
[22] Regorafenib for patients with progression of advanced hepatocellular carcinoma after treatment with atezolizumab plus bevacizumab: a case series
Kang, Wendi
Fu, Hongjiang
Luo, Yingen
Noreika, Danielle M.
Cong, Tianhao
Li, Hang
Yang, Zhengqiang
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 780 - 787
[23] Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
Yano, Yoshihiko
Yamamoto, Atsushi
Mimura, Takuya
Kushida, Saeko
Hirohata, Seiya
Yoon, Seitetsu
Hirano, Hirotaka
Kim, Soo Ki
Hatazawa, Yuri
Momose, Kenji
Hayashi, Hiroki
Kado, Takuo
Nishi, Katsuhisa
Tanaka, Hidenori
Matsuura, Takanori
Yoshida, Ryutaro
Asaji, Naoki
Yasutomi, Eiichiro
Shiomi, Yuuki
Minami, Akihiro
Komatsu, Shohei
Fukumoto, Takumi
Ueda, Yoshihide
Kodama, Yuzo
JGH OPEN, 2023, 7 (07): : 476 - 481
[24] Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
Castet, Florian
Willoughby, Catherine E.
Haber, Philipp K.
Llovet, Josep M.
CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1827 - 1829
[25] FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
Casak, Sandra J.
Donoghue, Martha
Fashoyin-Aje, Lola
Jiang, Xiaoping
Rodriguez, Lisa
Shen, Yuan-Li
Xu, Yuan
Jiang, Xiling
Liu, Jiang
Zhao, Hong
Pierce, William F.
Mehta, Shubhangi
Goldberg, Kirsten B.
Theoret, Marc R.
Kluetz, Paul G.
Pazdur, Richard
Lemery, Steven J.
CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1836 - 1841
[26] Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis
Hatanaka, Takeshi
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Naganuma, Atsushi
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Kouji
Iijima, Hiroko
Hiasa, Yoichi
Kumada, Takashi
HEPATOLOGY RESEARCH, 2022, 52 (05) : 462 - 470
[27] Evans’ syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma
Masanori Fukushima
Kazuaki Tajima
Ryu Sasaki
Yasuhiko Nakao
Kosuke Takahashi
Eisuke Ozawa
Satoshi Miuma
Takeharu Kato
Hisamitsu Miyaaki
Kazuhiko Nakao
Clinical Journal of Gastroenterology, 2023, 16 : 402 - 406
[28] Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma
Fukushima, Masanori
Tajima, Kazuaki
Sasaki, Ryu
Nakao, Yasuhiko
Takahashi, Kosuke
Ozawa, Eisuke
Miuma, Satoshi
Kato, Takeharu
Miyaaki, Hisamitsu
Nakao, Kazuhiko
CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (03) : 402 - 406
[29] Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors
Haghnejad, Vincent
Muller, Marie
Blaise, Lorraine
Gerolami, Rene
Bouattour, Mohamed
Assenat, Eric
Manfredi, Sylvain
Peron, Jean-Marie
Burcheri-Curatolo, Adriano
Lopez, Anthony
Ressiot, Emmnanuelle
Nahon, Pierre
Bronowicki, Jean-Pierre
DIGESTIVE AND LIVER DISEASE, 2023, 55 (07) : 938 - 944
[30] Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
Naoki Dosoden
Teiji Kuzuya
Yumi Ito
Jo Nishino
Eizaburo Ohno
Naoto Kawabe
Senju Hashimoto
Yoshiki Hirooka
Hidekata Yasuoka
Clinical Journal of Gastroenterology, 2023, 16 : 567 - 571

← 1 2 3 4 5 →